1Parkin D, Pisani P, Ferley J, et al. Global cancer statistics [ J ]. Ca Cancer J Clin, 1999,49 (3) :33 - 64.
2Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of US gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis [ J ]. Cancer,2000,88 (4) :921 -932.
3Naveenraj L. Solomon, Michael C. Cheung, Margaret M. Byrne, et al. Does Chemoradiotherapy Improve Outcomes for Surgically Resected Adenocarcinoma of the Stomach or Esophagus [ J ] ? Ann Surg Oncol, 2010, 17 ( 1 ) : 98 - 108.
4MacDonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenoeareinoma of the stomach or gastroesophageal junction [ J]. N Engl J Med, 2001,345 (10) :725 -730.
5Kozak KR, Moody JS: The survival impact of the intergroup 0116 trial on patients with gastric cancer [ J]. Int J Radiat Oncol Biol Phys ,2008,72 (2) :517 -521.
6Natalie G. Cobum, Ulrich Culler, et al : adjuvant therapy for resected gastric cancer-rapid, yet incomplete adoption following results of intergroup 0116 trial [ J]. Int J Radiat Oneol Biol Phys,2008,70(4) :1073 -1080.
7Kim S, Limdo H, Lee J, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach [ J ]. Int J Radiat Oncol Biol Phys ,2005,63 : 1279 - 1285.
8Lee J, Kang W, Lira D, et al. Phase III trial of adjuvant capecitabine/cisplatin (XP) compared with capecitabine/ cisplatin/RT (XPRT) in resected gastric cancer with D2 nodal dissection ( ARTIST trial) : Safety analysis. 2009 ASCO Annual Meeting [J]. J Clin Oncol,2009,27:15s.
9Jansen EPM, Boot H, Dubbelman R, et al. Postoperative chemoradiotherapy in gastric cancer-a phase I/II dosefinding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy [ J ]. Br J Cancer,2007,97 (6) :712 - 716.
10Edwin PMJ, Boot H, Saunders MP, et al. A phase I - II study of postoperative capecitabine-based chemoradio-therapy in gastric cancer [ J ]. Int J Radiat Oncol Biol Phys,2007,69 ( 5 ) : 1424 - 1428.
4Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med,2001,345:725-730.
5Jansen EP, Boot H, Sannders MP, et al. A phase I - II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys,2007,69:1424-1428.
6Kollmannsberger C, Budach W, Stahl M, et al. Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer:two cooperative phase II studies of the AIO/ARO/ACO. Ann Oncol,2005,16:1326-1333.
7Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA,2010,303 : 1729-1737.
8Orditura M, Martinelli E, Galizia G, et al Chemoradiotherapy as adjuvant treatment of gastric cancer. Ann Oncol, 2007,18 : 133- 135.
9Cavanna L, Zaniboni A, Artioli F, et al. Oxaliplatin (OXA), 5- fluorouracil (5-Fu) and leucovorin (LV) in patients with advanced or metastatic gastric cancer (A/MGC). J Clin Oncol, 2004,22:4068.
10PaoIetti X,Oba K,Burzykowaki T,etal.Chemoradiotherapy as adjuvant treatment of gastric cancer;a meta-analysis[J]. JAMA,2010,303:1792-1737.
